Danaher Quick Six – September 2022

1.    DANAHER ANNOUNCES INTENTION TO SEPARATE ENVIRONMENT & APPLIED SOLUTIONS SEGMENT TO CREATE AN INDEPENDENT, PUBLICLY TRADED COMPANY

Danaher’s Water Quality and Product Identification businesses will become a new, standalone company led by Jennifer Honeycutt. Target for completing the separation is in the fourth quarter of 2023, subject to conditions and approvals. 

"Danaher will become a more focused science and technology leader committed to innovation and making a profound impact on human health," said Danaher President & CEO Rainer Blair.

2.    DANAHER HOSTS INVESTOR DAY

Danaher held its Bioprocessing Investor and Analyst Meeting at Cytiva in Marlborough, Massachusetts on September 15, 2022. A video replay of the event, hosted by Rainer M. Blair, Danaher President & CEO, and Emmanuel Ligner, Vice President and Biotechnology Group Executive, is available to watch here. 

3.    TAPPING INTO ARTIFICIAL INTELLIGENCE FOR BETTER BEER

In the brewing industry, ensuring quality and efficiency means better beer. This month, Pall Corporation introduced Beer IoT, new technology enabling brewers to evaluate meaningful data in real-time and address potential issues before they impact product quality.

4.    CAN BIOPHARMA MAINTAIN ITS MOMENTUM?

While industries and individuals around the world experienced a pandemic-driven slow-down over the past several years, the biopharma industry is moving faster than ever. Danaher Chief Science Officer Jose-Carlos Gutierrez-Ramos discusses how we can capitalize on this momentum to collectively deliver many more new therapies to patients as quickly, safely, and effectively as possible.

5.    A CLOSER LOOK AT OUR PROVEN SYSTEM FOR SUCCESS

We offered several peeks behind the Danaher Business System curtain this month, with a new video and article about how DBS makes us different from every other company in the world. 

6.    mRNA IS TAKING THE FUTURE OF MEDICINE TO NEW HEIGHTS

mRNA continues demonstrating its promise in a variety of diverse ways, ushering in a “new golden age of vaccinology,” says Demaris Mills, President of Danaher OpCo Integrated DNA Technologies in Forbes.  “With years of mRNA clinical work built upon a foundation rooted in basic research, RNA-based vaccines will undoubtedly play a major role in the future of human health.”